Research programme: antibody therapeutics - Antitope/Byondis
Latest Information Update: 21 Apr 2020
At a glance
- Originator Antitope; Synthon
- Developer Antitope
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
- 28 Oct 2018 No recent reports of development identified for research development in Undefined in Netherlands
- 28 Oct 2018 No recent reports of development identified for research development in Undefined in United Kingdom